Latest EORTC Stories
NEW BRUNSWICK, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc.
VEDBAEK, Denmark, October 27 /PRNewswire-FirstCall/ -- The European Organization for Research and Treatment of Cancer (EORTC) has undertaken a multi-institutional prospective randomized clinical trial on 719 late stage epithelial ovarian cancer patients (named 55971).
CALGARY, Oct. 23 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that Dr.
Cougar Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced upcoming data and corporate presentations.
ARIAD Pharmaceuticals, Inc.
CALGARY, Sept. 22 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc.
KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sustained impact on relapse-free survival (RFS), according to results of a randomized phase III trial published in The Lancet today.
Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that a group of scientists lead by Professor Waldemar Priebe from The University of Texas M. D.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.